REG - Poolbeg Pharma PLC - Interim Results for the six months to 30 June 2025
Yesterday 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250929:nRSc0910Ba&default-theme=true
RNS Number : 0910B Poolbeg Pharma PLC 29 September 2025
Poolbeg Pharma plc
Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones
29 September 2025 - Poolbeg Pharma
(https://url.avanan.click/v2/r02/___https:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86NDU2MjEwNTM4MTFlNTUzMTE4ZWFkNDJmMTFlNDI2Zjg6NzphNGRhOmIyMjkxODcwZWMyY2YyYTc4MDU5ZjAzOGYxMjJmMjZmMDAxMzM2YjhhNTczZmQxNjljOTgwZGNhZWM4ZGQzZTU6cDpGOk4)
(AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company with a core focus on transforming the cancer
immunotherapy field, announces its unaudited interim results for the six
months to 30 June 2025.
Highlights & Updates
• Cash balance of £10.0 million as at 30 June 2025, including £4.865 million
gross proceeds raised as part of an oversubscribed and upsized fundraise
• Cash runway extended into 2027, supporting the delivery of multiple key
clinical milestones
• Specialist blood cancer trials organisation Accelerating Clinical Trials
Limited appointed to conduct POLB 001 Phase 2a trial, and supply of an
approved bispecific antibody drug secured for the trial at no cost to the
Company
• Trial due to take place at The Christie NHS Foundation Trust and other leading
UK specialist cancer centres, with interim data expected summer 2026
• POLB 001 granted Orphan Drug Designation by FDA as an oral preventative
therapy for T-cell engager bispecific antibody-induced Cytokine Release
Syndrome ("CRS"), further validating POLB 001's scientific rationale and
enhancing its commercial appeal
• Positive data from an in vivo animal study in H1 2025 supported the use of
POLB 001 to prevent CRS induced by T-cell engaging bispecific antibody
therapies
• Progress made towards commencement of oral GLP-1 proof of concept trial at
University of Ulster, led by Prof Carel le Roux with up to 20 obese subjects,
with topline data expected H1 2026
• The Company's pipeline programmes are in areas of significant interest to the
pharmaceutical industry and as such, Poolbeg anticipates strong potential for
partnering on positive data from the forthcoming clinical trials
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: "We
have made excellent progress this year and have entered a catalyst-rich period
for Poolbeg. Preparations for the POLB 001 Phase 2a trial are well advanced,
with the approved bispecific antibody secured at no cost to the Company. The
data from this study will further strengthen our extensive preclinical and
clinical package, supported by the recent FDA Orphan Drug Designation, which
underscores the strong scientific rationale behind POLB 001 and enhances its
commercial appeal with prospective partners.
"Looking ahead, we anticipate a series of potential value-creating milestones
as data emerges from our POLB 001 and Oral GLP-1 trials in 2026. This,
combined with a robust cash runway and a team with proven expertise in
clinical trial execution and deal-making, means that we believe we are well
positioned to deliver value for shareholders. We look forward to providing
further updates to the market in due course."
Enquiries
Poolbeg Pharma Plc +44 (0) 207 183 1499
Jeremy Skillington, CEO ir@poolbegpharma.com
Ian O'Connell, CFO
Cavendish Capital Markets Ltd (NOMAD & Joint Broker) +44 (0) 207 220 0500
Geoff Nash, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Harriet Ward (ECM)
Shore Capital Stockbrokers Ltd (Joint Broker) +44 (0) 207 408 4090
David Coaten, Harry Davies-Ball (Corporate Advisory)
Malachy McEntyre (Corporate Broking)
J&E Davy (Joint Broker) +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Vici Rabbetts, Elena Bates poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)
About Poolbeg Pharma plc
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage
biopharmaceutical company with a core focus on transforming the cancer
immunotherapy field. The Company's lead asset, POLB 001, has the potential to
expand administration of cancer immunotherapies from centralised specialist
cancer centres into community hospitals by making the treatments safer through
the prevention of the life-threatening side effect, Cytokine Release Syndrome
(CRS). As such, POLB 001 could increase the number of patients that can
receive these life-saving treatments, thereby increasing the market
opportunity. Poolbeg is also advancing the development of a patient-friendly
therapy for obesity with an oral encapsulated GLP-1, offering a differentiated
approach within one of the world's largest markets. With multiple near-term
clinical value inflection points, and an experienced team with a proven track
record, Poolbeg is focussed on partnering its high value programmes that are
targeting large markets and addressing critical unmet medical needs.
Stay updated: Website
(https://url.avanan.click/v2/r02/___http:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86NGFjYzZiZmUwNzdlMzg3YjY1ODM2OTgxYzEzMzlmNjk6NzozODZjOmZkNDQ2MWU4N2FjYzgzNTcxOWY2MjFjNDVmZjQyMDIxZWE4NDJjOGE0YzNlNTk0MTQ4YTZkYjZmMGU0YTE2Yjk6cDpGOk4)
| Sign up for RNS alerts
(https://url.avanan.click/v2/r02/___https:/www.poolbegpharma.com/investors/regulatory-news-email-alerts/___.YXAxZTpzaG9yZWNhcDphOm86NGFjYzZiZmUwNzdlMzg3YjY1ODM2OTgxYzEzMzlmNjk6NzoxZGI2OjZmNDJlOGY0MDcxMTczYmVmOGJmM2JjMWQxZTVlN2MzYjEyYmQ1MWZjYmQzMTY1ZWRiZGNkZTYyMjA0MWEwMDE6cDpGOk4#email-alerts)
| Presentation
(https://url.avanan.click/v2/r02/___https:/www.poolbegpharma.com/investors/events-presentations/___.YXAxZTpzaG9yZWNhcDphOm86NGFjYzZiZmUwNzdlMzg3YjY1ODM2OTgxYzEzMzlmNjk6NzoxOWQwOmY2ODQ0MzE0NGZmZTA3MWI1MDRmNDEyNDVlM2UyZjhjNGQwZjBjYTAxYzlmYmY3NzQ5YWI1M2NjZGUwYTQ5MTk6cDpGOk4)
| X
(https://url.avanan.click/v2/r02/___https:/x.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDphOm86NGFjYzZiZmUwNzdlMzg3YjY1ODM2OTgxYzEzMzlmNjk6NzpjZmJiOjczZDhiNWNlNzg1NmQ5N2I4MjRmYzM0ODcxODA4ZGYxMTc4OWY3MzMzMTkyMTVlNWJlNTJlZDVhZDVjNmE5YWY6cDpGOk4)
| LinkedIn
(https://url.avanan.click/v2/r02/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDphOm86NGFjYzZiZmUwNzdlMzg3YjY1ODM2OTgxYzEzMzlmNjk6NzphNDY3OjA0ZDZlOGYwNGZlOTkxMTQ0NGMzNDM1ZjU4YjBhNTE3MWQ5MmRmYTU0OTExODMzZjNiNTU5MDYwMmNkZDY2Nzc6cDpGOk4)
Forward-Looking Statements
This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.
CEO Statement
I am delighted to present the unaudited Interim Financial Statements
of Poolbeg Pharma plc for the six months to 30 June 2025.
We made strong progress across our pipeline in H1 2025, and were pleased to
have seen such significant interest from investors in our oversubscribed and
upsized fundraise. The £4.865 million gross proceeds raised, together with
our existing resources, extends our cash runway into 2027 and will support the
delivery of multiple key clinical milestones in oncology and obesity - two
areas of high strategic value and growing interest within the pharmaceutical
industry - as we continue to progress toward partnering our programmes.
Strong progress across the pipeline
POLB 001 - potential US$10 billion market opportunity(1)
POLB 001 is potentially a breakthrough, orally delivered, p38 MAPK inhibitor
to prevent cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"),
with further life cycle opportunities, including severe influenza. CRS is a
severe and potentially life-threatening side effect of cancer immunotherapies.
Over 70% of patients undergoing treatment with certain T-cell engaging
bispecific antibodies or CAR T-cell therapies are affected.(2) Due to the risk
of CRS, treatment is restricted to specialist cancer centres causing extended
hospitalisation, high consumption of healthcare resources, and ultimately a
reduced uptake of treatment due to accessibility or capacity limitations. With
no approved therapies for the prevention of cancer immunotherapy-induced CRS,
POLB 001 represents a significant opportunity to transform the field of cancer
immunotherapies. By making the treatments safer, through the prevention of
CRS, administration of cancer immunotherapies can be expanded from centralised
specialist cancer centres into community hospitals. As such, POLB 001 could
increase the number of patients that can receive these life-saving treatments,
further increasing the market opportunity.
As a preventative therapy for cancer immunotherapy-induced CRS, we believe
that POLB 001 has a market opportunity exceeding US$10 billion. This estimate
accounts for multiple myeloma and diffuse large B-cell lymphoma patients
alone, two indications in which cancer immunotherapies have a dominant
position for the treatment of late-stage disease. However, we believe this is
a conservative estimate, as the demand for CRS management may increase as
immunotherapies are developed for a wider range of haematological malignancies
(blood cancers) and solid tumours.
In May 2025, the US Food and Drug Administration ("FDA") granted Orphan Drug
Designation to POLB 001 as an oral preventative therapy for T-cell engager
bispecific antibody-induced CRS. Orphan Drug Designation provides Poolbeg with
potential clinical development and commercialisation benefits, including a
seven-year period of US market exclusivity following regulatory approval of
POLB 001, waiver of Prescription Drug User Fee Act application fees (valued
at over US$4 million), earlier access to Special Protocol Assessment to agree
on pivotal trial designs, and the potential for tax credits for qualifying
clinical trials.
POLB 001 has demonstrated a compelling safety and efficacy profile in both
preclinical and clinical settings. Results from the 2023 human LPS challenge
trial and 2024 in vivo animal study have significantly de-risked the upcoming
Phase 2a trial. Further favourable data in a new in vivo animal study in H1
2025 supported the use of POLB 001 as a preventative for CRS induced by T-cell
engaging bispecific antibody therapies such as approved breakthrough
therapeutics teclistamab, elranatamab, talquetamab and others. POLB 001 has a
favourable safety and tolerability profile and, importantly, it selectively
prevents excessive inflammation without immunosuppression, particularly
pertinent in vulnerable patient populations, like cancer patients, who must
maintain functional immune responses.
We signed an agreement for a specialist blood cancer trials organisation,
Accelerating Clinical Trials Limited ("ACT"), to conduct the upcoming POLB 001
Phase 2a trial. We are pleased to have secured the supply of an approved
bispecific antibody drug for the trial at no cost to the Company and are now
at an advanced stage of trial preparations. The study will be led by Dr Emma
Searle, Consultant Haematologist at The Christie NHS Foundation Trust,
Honorary Senior Lecturer at the University of Manchester, as well as Chair of
the British Society of Haematology Research and Grants Committee. The
Christie, a leading cancer research institute based in Manchester, and a
number of other leading UK specialist cancer centres will participate. This
open-label, single-arm trial will evaluate POLB 001 in approximately 30
relapsed, refractory, multiple myeloma patients receiving an approved
bispecific antibody. We are encouraged by the interest from leading myeloma
clinicians that have expressed interest in participating in the upcoming
trial, which reinforces the positive feedback received to date from key
opinion leaders in the space.
We are on track to deliver clinical data in 2026 and look forward to sharing
this data with prospective partners, we see strong potential for partnering on
positive data from the forthcoming trial. The demand for effective CRS
prevention solutions is driven by rapid growth of CRS-inducing cancer
immunotherapies, a market which is expected to grow to US$120 billion by
2030.(3,4,5) In addition, the recent FDA Orphan Drug Designation further
validates POLB 001's scientific rationale and enhances its commercial appeal
for prospective partners. If approved, POLB 001 has the potential to
revolutionise cancer immunotherapy delivery by making it safer, enabling
administration in community hospitals, reducing healthcare burden, and
ultimately expanding patient access to these life-saving treatments.
Oral encapsulated GLP-1 programme targeting the obesity market
Our oral encapsulated GLP-1 programme leverages a proprietary delivery system
that encapsulates APIs (active pharmaceutical ingredients) using Generally
Recognised as Safe (GRAS) components. This approach targets delivery to
specific areas of the gut and into systemic circulation, with the potential to
improve convenience and bioavailability, for the treatment of metabolic
disorders, such as obesity. The effectiveness of the technology has already
been validated via the commercialisation of encapsulated oral probiotics and
nutraceuticals by our partner, AnaBio Technologies.
Obesity has been recognised by the World Health Organization (WHO) as a major
global health challenge, reaching epidemic levels. According to the US Centers
for Disease Control and Prevention (CDC), approximately 42% of the US
population is currently affected(6). In 2023, obesity-related issues were
estimated to have cost US businesses and their employees around US$347.5
billion(7). These factors have contributed to the rapid rise in demand for
prescription weight loss treatments, notably glucagon-like peptide 1 receptor
agonists ("GLP-1R"). The global GLP-1R market is forecast to grow
significantly, expected to reach US$150 billion by 2031 across obesity and
diabetes indications alone(8).
Oral GLP-1R options remain limited yet highly sought after owing to their
non-invasiveness, ease of access and greater patient compliance, particularly
those with chronic conditions who require long-term treatment. There are
major shortcomings within currently approved injectable treatment options,
with 65% of patients who discontinued GLP-1s within one year stating they
would prefer oral alternatives(9). There is currently only one oral GLP-1R
agonist on the market with a bioavailability of just c.1%(10). Our licensed
technology has the potential to overcome challenges associated with oral
delivery of peptide-based biologics, offering a differentiated approach within
one of the world's largest markets.
Our proof-of-concept clinical trial will take place at the University of
Ulster, led by a team that includes Professor Carel le Roux, a notable figure
in the field of metabolic medicine. The trial is designed to generate
impactful data, expected in H1 2026, that demonstrates the ability to safely
and efficiently deliver our oral GLP-1 in up to 20 obese subjects. We continue
to keep potential pharma partners updated on the progress of this trial and we
believe there is potential for partnering on positive data. As Poolbeg holds a
licence to this proprietary oral encapsulation technology across all metabolic
conditions, there is also further partnering opportunities beyond GLP-1 and
the successful results from the trial may provide technology validation to
support multiple opportunities for value creation.
Artificial Intelligence ("AI") Programmes
Whilst we are currently prioritising the upcoming clinical trials for POLB 001
and our Oral GLP-1 programme, discussions in respect to potential
collaborations of our AI-led programmes are ongoing. AI-driven drug discovery
is seeing continued global interest as it has the potential to accelerate
target identification, reduce costs, de-risk development, and improve success
rates. We successfully identified multiple novel drug targets and new
potential drug candidates for Influenza and Respiratory Syncytial Virus
("RSV") respectively - with multiple partnering opportunities from each
programme.
Financial
During the period, the Company strengthened its financial position by
completing a £4.865m (before expenses) fundraise at 2.5p per share. This
resulted in a cash balance of £10.0 million as at 30 June 2025 (30 June
2024: £10.1 million) and extends Poolbeg's financial runway into 2027
supporting the delivery of multiple key clinical milestones. To align
resourcing with these near-term clinical priorities, the Company implemented a
series of operational efficiency measures, including selective headcount
reductions. These changes are expected to streamline the cost base and
maintain focus on the delivery of key clinical milestones through 2026 and
into 2027.
The loss for the period amounted to £2.2 million (H1 24: £2.3 million)
comprised of R&D expenses of £0.5 million (H1 24: £0.7 million),
administrative expenses £2.0 million (H1 24: £2.1 million), and tax
rebates and other income & charges of £0.4 million (H1 24: £0.6
million).
Outlook
Our programmes are in areas of high interest within the pharmaceutical
industry. We are optimistic about the potential of POLB 001 to transform the
delivery of cancer immunotherapies by moving administration away from
specialist centralised cancer centres and into the community setting, closer
to patients' homes and, as a result, making these life-saving treatments
available to more patients. POLB 001 has the potential to make cancer
immunotherapies safer by reducing the incidence of cancer immunotherapy-CRS
which can be potentially life threatening. This is supported by strong
pre-clinical and clinical data generated to date, robust intellectual
property, global rights, and FDA Orphan Drug Designation for POLB 001. In
addition, our patient-friendly oral encapsulated GLP-1 for obesity offers a
differentiated approach within one of the world's largest markets.
I am excited about Poolbeg's future; we've entered a catalyst-rich period,
supported by a robust cash balance that provides runway through to 2027. With
a clear plan to deliver shareholder value through our clinical programmes, we
are led by a proven team with expertise in clinical execution and deal-making
and we see strong potential to secure partnerships based on positive data from
our upcoming trials.
Jeremy Skillington
CEO
26 September 2025
References
1.Independent research by Decisive Consulting Limited.
2. Average rate from Summary of Product Characteristics (SmPCs) for Yescarta,
Tecartus, Abecma, Kymriah, Carvykti, Breyanzi, Elrexfio, Columvi, Epkinly,
Tecvayli and Talvey;
3. Grand View Research. CAR T-Cell Therapy Market Analysis 2023-2030.
4. Grand View Research. Bispecific Antibodies Market Size, Share & Trends
Analysis Report.
5.Datamonitor Healthcare. Forecast: Diffuse Large B-Cell Lymphoma and Multiple
Myeloma, 2023.
6. Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition
Examination Survey 2017-March 2020 prepandemic data files development of files
and prevalence estimates for selected health outcomes. Natl Health Stat
Report. 2021;158.
7. Global Data, Assessing the Economic Impact of Obesity and Overweight on
Employers, Feb 2024.
8. The Economist, March 2023.
9. PMID: 29033597.
10. EMA Product information 2020
Consolidated Statement of Comprehensive Income
For the six months to 30 June 2025
Unaudited Unaudited Audited
Six months to Six months to Year ended
30 June 2025 30 June 2024 31 December 2024
Note £'000 £'000 £'000
Revenue - - -
Cost of sales - - -
Gross profit - - -
Administrative expenses (2,031) (2,113) (5,258)
Other operating income 209 285 530
Research and development expenses (527) (701) (1,383)
Net losses on disposal of assets - - (261)
Operating loss (2,349) (2,529) (6,372)
Finance income 116 246 428
Loss before income tax (2,233) (2,283) (5,944)
Taxation 55 25 154
Loss and total comprehensive loss for the period attributable to the equity (2,178) (2,258) (5,790)
holders of the Company
Loss per share:
Loss per share - basic and diluted, attributable to ordinary equity holders of (0.43)p (0.45)p (1.16)p
the parent
3
Consolidated Statement of Financial Position
As at 30 June 2025
Unaudited Unaudited Audited
30 June 2025 30 June 2024 31 December 2024
Note £'000 £'000 £'000
Assets
Non-current assets
Intangible assets 4 1,662 2,011 1,684
Total non-current assets 1,662 2,011 1,684
Current assets
Trade and other receivables 5 738 938 739
Cash and cash equivalents 9,961 10,061 7,824
Total current assets 10,699 10,999 8,563
Total assets 12,361 13,010 10,247
Equity and liabilities
Equity attributable to owners of the parent
Share capital 139 100 100
Share premium 27,548 23,100 23,100
Other reserves 3,166 2,460 2,816
Accumulated deficit (18,921) (13,211) (16,743)
Total equity 11,932 12,449 9,273
Current liabilities
Trade and other payables 429 561 974
Total current liabilities 429 561 974
Total liabilities 429 561 974
Total equity and liabilities 12,361 13,010 10,247
Consolidated Statement of Changes in Equity
For the six months to 30 June 2025
Share Share Share based payment reserve Merger Accumulated deficit
capital premium reserve Total
Note £'000 £'000 £'000 £'000 £'000 £'000
At 1 January 2024 100 23,100 740 1,455 (10,953) 14,442
Loss and total comprehensive loss for the period - - - - (2,258) (2,258)
Share based payments - - 265 - - 265
Balance at 30 June 2024 100 23,100 1,005 1,455 (13,211) 12,449
Loss and total comprehensive loss for the period - - - - (3,532) (3,532)
Share based payments - - 356 - - 356
Balance at 31 December 2024 100 23,100 1,361 1,455 (16,743) 9,273
Loss and total comprehensive loss for the period - - - - (2,178) (2,178)
Issue of fee shares 3 - 65 - - - 65
Issue of shares for cash 3 39 4,826 - - - 4,865
Costs charged against share premium - (443) - - - (443)
Share based payments - - 350 - - 350
Balance at 30 June 2025 139 27,548 1,711 1,455 (18,921) 11,932
Consolidated Statement of Cash Flows
For the six months to 30 June 2025
Unaudited Unaudited Audited
Six months to Six months to Year ended
30 June 2025 30 June 2024 31 December 2024
Note £'000 £'000 £'000
Cash flows from operating activities
Loss on ordinary activities before taxation (2,233) (2,283) (5,944)
Amortisation 4 26 13 114
Disposal of intangible assets - - 261
Share based payment expense 350 265 621
Finance income (116) (246) (428)
R&D tax credits - 424 595
Movements in working capital and other adjustments:
Change in trade and other receivables 5 56 (10) 147
Change in trade and other payables (545) (425) (12)
Net cash flow used in operating activities (2,462) (2,262) (4,646)
Cash flow from investing activities
Payments for intangible assets 4 (4) (94) (129)
Interest received from bank 116 246 428
Net cash flow from investing activities 112 152 299
Cash flow from financing activities
Net proceeds from issue of equity instruments 4,487 - -
Net cash flow from financing activities 4,487 - -
Net change in cash and cash equivalents 2,137 (2,110) (4,347)
Cash and cash equivalents at beginning of period 7,824 12,171 12,171
Cash and cash equivalents at end of period 9,961 10,061 7,824
Notes to the Interim Results
1. General information
Poolbeg Pharma plc ("Poolbeg" or the "Company") is a public limited company
incorporated in England and Wales with company number 13279507. The Company is
listed on the AIM market of the London Stock Exchange (ticker: POLB.L, ISIN:
GB00BKPG7Z60).
Poolbeg is a clinical-stage biopharmaceutical company focussed on acquiring,
developing and commercialising innovative medicines that will help improve the
lives of patients with serious diseases and where there is a high unmet
medical need.
2. Basis of preparation
The Interim Results of the Company for the six months to 30 June 2025 comprise
those of the Company and its subsidiaries (together the "Group"). The Interim
Results have been prepared on the going concern basis under the historical
cost convention in accordance with the recognition and measurement
requirements of United Kingdom adopted International Accounting Standards
("IFRS") and their interpretations issued by the International Accounting
Standards Board ("IASB"), and in accordance with those parts of the Companies
Act 2006 applicable to companies reporting under IFRS. As is permitted by the
AIM rules, the Directors have not adopted the requirements of IAS 34 "Interim
Financial Reporting" in preparing the financial statements. Accordingly, the
financial statements are not in full compliance with IFRS and have neither
been audited nor reviewed pursuant to guidance issued by the Auditing
Practices Board.
The financial information for the six months to 30 June 2025 and 30 June 2024
is unaudited. The information for the year ended 31 December 2024 has been
extracted from the Company's audited accounts on which the auditors issued an
unqualified audit opinion. The information presented for that period does not
constitute full accounts for that period. The 31 December 2024 audited
accounts have been delivered to the Companies House.
The financial information is presented in £ which is the functional and
presentational currency of the Company. Balances are rounded to the nearest
thousand (£'000) except where otherwise indicated.
The Interim Results were approved by the Board of Directors on 26 September
2025.
The accounting policies used in the preparation of the Interim Results are
consistent with those used in the Company's audited financial statements for
the year to 31 December 2024.
3. Loss per share - basic and diluted
The Group presents basic and diluted loss per share ("LPS") data for its
ordinary shares. Basic LPS is calculated by dividing the loss attributable to
ordinary shareholders of the Company by the weighted average number of
ordinary shares outstanding during the period. Diluted LPS is determined by
adjusting the loss attributable to ordinary shareholders and the weighted
average number of ordinary shares outstanding for the effects of all dilutive
potential ordinary shares, which comprise warrants and share options granted
by the Company.
Issued share capital - ordinary shares of 0.02p each
Share Issue Details Number of shares Weighted average shares
30 June 2024 & 31 December 2024 500,000,000 500,000,000
25 June 2025 - share placing & fee shares 197,200,000
30 June 2025 697,200,000 506,537,017
On 25 June 2025, 194,600,000 ordinary shares of 0.02p were issued at 2.5p per
share as part of a £4,865,000 (before expenses) fund raising. In addition, as
part of the fundraising arrangements, the Company issued 2,600,000 ordinary
shares at the issue price to advisors in lieu of advisory fees.
The calculation of loss per share is based on the following:
Unaudited Unaudited Audited
Six months ended Six months ended Year ended
30 June 2025 30 June 2024 31 December 2024
Loss after tax attributable to equity holders of the Company (£'000) (2,178) (2,258) (5,790)
Weighted average number of ordinary shares in issue 506,537,017 500,000,000 500,000,000
Fully diluted average number of ordinary shares in issue 506,537,017 500,000,000 500,000,000
Basic and diluted loss per share (0.43)p (0.45)p (1.16)p
Under IAS 33.43 "Earnings per Share", the calculation of loss per share does
not assume conversion, exercise, or other issue of potential shares that would
have an antidilutive effect on LPS. For the current and comparative periods,
the effect of options would be to reduce the loss per share and as such the
basic and diluted LPS are the same. There were 65,076,600 share options and
warrants outstanding as at 30 June 2025 (30 June 2024 and 31 December 2024:
65,076,600) and these are potentially dilutive.
4. Intangible assets
Acquired Licences & Data Patents & Trademarks
Total
£'000 £'000 £'000
Cost
At 31 December 2023 1,964 389 2,353
Additions - 129 129
Disposals (443) (171) (614)
At 31 December 2024 1,521 347 1,868
Additions - 4 4
At 30 June 2025 1,521 351 1,872
Amortisation and impairment
At 31 December 2023 318 105 423
Amortisation charge 25 89 114
Disposals (250) (103) (353)
At 31 December 2024 93 91 184
Amortisation charge 12 14 26
At 30 June 2025 105 105 210
Net book value
Net book value at 30 June 2025 1,416 246 1,662
Net book value at 31 December 2024 1,428 256 1,684
5. Trade and other receivables
Unaudited Unaudited Audited
30 June 2025 30 June 2024 31 December 2024
£'000 £'000 £'000
Accounts receivables 3 11 20
Prepayments and accrued income 395 627 465
Grant receivable 61 75 34
VAT recoverable 91 50 87
R&D tax credit 188 175 133
Trade and other receivables 738 938 739
6. Events after the reporting period
On 25 September 2025, Poolbeg announced that it had signed an agreement for a
specialist blood cancer trials organisation, Accelerating Clinical Trials
Limited ("ACT"), to conduct the upcoming POLB 001 Phase 2a trial. The trial is
due to take place at The Christie NHS Foundation Trust and other leading UK
specialist cancer centres, with interim data expected in summer 2026.
7. Copy of the interim results
A copy of the Company's Interim Results for the six months to 30 June 2025 is
available on the Company's
website, www.poolbegpharma.com/investors/documents/
(https://url.avanan.click/v2/r02/___http:/www.poolbegpharma.com/investors/documents/___.YXAxZTpzaG9yZWNhcDphOm86NGFjYzZiZmUwNzdlMzg3YjY1ODM2OTgxYzEzMzlmNjk6NzpkMzFkOmU0ZTBkZjgzZGNhZDA3NzMyMzljNGE2MDRlZjBhZjRjNWMxODQ0MTdlNjA4OGM4MjVkMjQyY2NiZjIyMmU1NzM6cDpGOk4)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR PPURCBUPAGQQRecent news on Poolbeg Pharma
See all newsREG - Poolbeg Pharma PLC - Interim Results for the six months to 30 June 2025
AnnouncementREG - Poolbeg Pharma PLC - POLB 001 Phase 2a Trial Update
AnnouncementREG - Poolbeg Pharma PLC - Notification of Major Holdings
AnnouncementREG - Poolbeg Pharma PLC - Notification of Major Holdings
AnnouncementREG - AIM - AIM Notice - 25/06/2025
Announcement